Direct-to-Biology (D2B) workflows overcome PROTAC and molecular glue-specific challenges, streamlining design–make–test cycles.

An integrated model approach allows you to reduce handoffs and shorten timelines by reducing time to decision, ensuring each compound is evaluated not just for degradation but for real drug-like potential.

Download the infographic to see the complete workflow, from advanced CADD to through to optimized candidates.